Delivra Health Brands (DHB) AI Stock Analysis

• Market Cap: C$6.56M
• Dividend Yield: N/A
• Average Volume (3M): 6.87K
• Price to Earnings (P/E): 181.8
• Beta (1Y): -0.27
• Revenue Growth: 4.04%
• EPS Growth: 80.24%
• Country: CA
• Employees: 22
• Sector: General
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 31,261,782
• 10 Day Avg. Volume: 4,736
• 30 Day Avg. Volume: 6,871
• PEG Ratio: 1.41
• Price to Book (P/B): 7.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -22.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.72
• Price Target Upside: 227.27% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 60 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

Delivra Health Brands shows potential through improving financial performance and strategic corporate events. However, technical indicators reflect a mixed sentiment, and valuation metrics raise caution due to unprofitability. The company's strategic initiatives and cash flow improvements are positive, but profitability remains a key challenge to address.

Delivra Health Brands Business Overview & Revenue Model

Company Description

Delivra Health Brands (DHB) operates within the health and wellness sector, focusing on the development and commercialization of innovative delivery systems for active ingredients. The company specializes in creating topical and transdermal formulations designed to enhance the absorption and efficacy of various compounds. DHB's core products include a range of creams, gels, and other topical solutions aimed at addressing pain management, skincare, and other health-related concerns.

How the Company Makes Money

Delivra Health Brands generates revenue primarily through the sale of its proprietary topical and transdermal products. The company markets these products directly to consumers as well as through partnerships with retailers and distributors in the health and wellness industry. In addition to direct product sales, DHB may also engage in licensing agreements, allowing other companies to utilize its patented delivery technologies in their own product lines. Significant partnerships with healthcare providers or retail chains can amplify distribution and sales, further contributing to the company's earnings. Additionally, the company may invest in research and development to continue innovating and expanding its product offerings, which can lead to new revenue streams.

Delivra Health Brands Financial Statement Overview

Summary

Delivra Health Brands is experiencing positive revenue growth and improved gross profit margins. However, negative EBIT margins and low net profitability are areas of concern. The balance sheet shows stable equity and manageable debt levels, while cash flow improvements indicate better operational efficiency. Continued focus on cost management is crucial.

Income Statement

Delivra Health Brands has shown positive trends in revenue growth, with an increase from $9.79M in 2023 to $12.57M in TTM, resulting in a 28.4% growth rate. The gross profit margin has improved significantly to 47.2% in TTM, indicating better cost management. However, the company is struggling with negative EBIT margins and thin net profit margins, which could be a concern for long-term profitability.

Balance Sheet

The balance sheet shows a relatively stable equity base with a debt-to-equity ratio of 0.50 in TTM, indicating modest leverage. The equity ratio stands at 50.9%, showing solid equity financing. However, the return on equity is minimal at 0.14%, reflecting the challenge in generating returns from equity capital.

Cash Flow

The cash flow statement highlights a positive trend in free cash flow, which increased from negative values to $407K in TTM. The operating cash flow to net income ratio is high, indicating strong cash generation relative to reported profits. The company needs to maintain this momentum to ensure liquidity and operational flexibility.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	12.57M	12.38M	9.79M	8.14M	7.96M	7.78M
Gross Profit	5.94M	6.40M	3.49M	485.00K	-297.00K	-1.62M
EBITDA	1.58M	2.35M	1.40M	-4.25M	-7.04M	-55.40M
Net Income	6.00K	876.00K	-184.00K	-7.01M	-28.54M	-79.86M
Balance Sheet
Total Assets	15.09M	10.05M	10.56M	11.59M	19.06M	57.84M
Cash, Cash Equivalents and Short-Term Investments	2.83M	4.20M	2.73M	1.11M	5.14M	1.41M
Total Debt	2.09M	2.03M	1.96M	2.11M	2.16M	5.97M
Total Liabilities	7.95M	4.86M	7.17M	8.21M	9.09M	21.27M
Stockholders Equity	7.14M	5.19M	3.39M	3.37M	9.98M	33.52M
Cash Flow
Free Cash Flow	407.00K	756.00K	-1.13M	-4.46M	-9.68M	-24.67M
Operating Cash Flow	407.00K	756.00K	-1.09M	-4.44M	-9.65M	-18.36M
Investing Cash Flow	0.00	11.00K	2.91M	1.35M	12.27M	-3.64M
Financing Cash Flow	-140.00K	594.00K	-255.00K	-309.00K	446.00K	3.17M

Delivra Health Brands Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DHB, the sentiment is Positive. The current price of 0.22 is above the 20-day moving average (MA) of 0.20, above the 50-day MA of 0.20, and above the 200-day MA of 0.19, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.25 is Neutral, neither overbought nor oversold. The STOCH value of 88.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DHB.

Delivra Health Brands Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DHB	60 Neutral	C$6.56M	181.82	-3.45%	―	4.04%	80.24%
BBM	53 Neutral	$7.43M	―	-112.06%	―	46.27%	20.75%
CANB	51 Neutral	C$5.53M	80.00	0.83%	―	-8.84%	-96.82%
IMCC	51 Neutral	$9.13M	―	-63.75%	―	9.34%	69.69%
Sector *	50 Neutral	C$8.24M	-12.27	-14.17%	11.18%	220.52%	64.21%
ATLE	46 Neutral	C$91.58M	―	-971.43%	―	571.23%	64.25%

Delivra Health Brands Corporate Events

Delivra Health Expands U.S. Reach Through QVC Partnership

Delivra Health Brands has expanded its U.S. presence by partnering with QVC, a major televised and online shopping network. This collaboration will enhance the distribution and visibility of its Dream Water Snoozeberry Sleep Shots, potentially increasing brand loyalty and consumer engagement through QVC’s unique shopping experience.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.09 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Delivra Health Brands Enhances Investor Relations with New Partnerships

Delivra Health Brands Inc. has engaged Global One Media and Bergskogar Limited for investor relations services to enhance its digital marketing and global business development efforts. These collaborations are expected to strengthen Delivra Health’s market presence and visibility, potentially impacting its operations and stakeholder interests positively.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.09 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Delivra Health Achieves Positive Q3 EBITDA Amid Strategic Marketing Push

Delivra Health Brands reported a positive adjusted EBITDA for the third quarter of fiscal 2025, driven by strong marketing momentum and growth in units sold. The company achieved a 3% year-over-year revenue increase and expanded its Dream Water product offerings in Canada, while also launching successful marketing campaigns for its LivRelief brand. Despite a reduction in gross profit margin due to higher costs, Delivra Health’s strategic investments in marketing and product innovation have laid a strong foundation for future growth.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.09 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Delivra Health Expands Dream Water® Brand with New Product Launch in Middle East

Delivra Health Brands Inc. is expanding its Dream Water® product line by launching 60-Count Sleep Gummies in the Middle Eastern markets through its Kuwait-based distributor. This strategic move is expected to enhance the brand’s presence and growth in new markets, leveraging the success of its sleep solutions in Canada and the U.S., and offering more choices to consumers in the region.